Core Insights - The company delivered 2025 sales and adjusted EPS at the high end of guidance, driven by 6% organic growth and 13% adjusted operating income expansion [1] - Strong performance in 2025 is attributed to new product ramps in electrophysiology, robust neurovascular demand, and successful integration of recent acquisitions [1] - A revenue headwind of 3% to 4% is identified for 2026 due to lower-than-anticipated market adoption of three specific new products in electrophysiology and neuromodulation [1] - The underlying core business remains healthy, with expected growth of 4% to 6% in 2026 when excluding the three underperforming products [1] - The company emphasizes a long-term strategy of engaging early in the design phase to accelerate customer innovation and simplify global supply chains [1] - A 300% increase in product development sales since 2017 is reported, viewed as a leading indicator for future commercial manufacturing contributions [1] - Commitment to a high-performance culture focused on the Integer Production System to drive operational excellence and margin expansion is affirmed [1]